UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000012179
Receipt number R000014038
Scientific Title Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study
Date of disclosure of the study information 2013/10/31
Last modified on 2022/07/16 20:17:56

No. Disposal Last modified on Item of update
1 Insert 2013/10/31 10:26:25
2 Update 2013/10/31 10:35:12 Date of disclosure of the study information
3 Update 2014/03/06 13:24:49 Division name
Division name
4 Update 2014/04/30 15:45:43 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
5 Update 2014/04/30 15:49:37 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
6 Update 2014/06/09 17:24:04 Name of person sending information
Name of person sending information
Organization
Organization
Division name
Division name
Address
Address
TEL
Email
7 Update 2014/10/31 16:36:58 Organization
Organization
Division name
Division name
Address
Address
TEL
Email
Address
Address
TEL
Address
Address
TEL
8 Update 2014/10/31 16:50:40 Institutions
9 Update 2015/11/30 11:13:31 Last follow-up date
10 Update 2016/05/09 09:15:42 Name of primary person or sponsor
Organization
11 Update 2016/07/08 15:41:00 Recruitment status
12 Update 2017/05/08 09:24:28 Last follow-up date
13 Update 2018/08/23 17:41:54 Public title
14 Update 2018/08/24 10:09:01 UMIN ID1
15 Update 2018/11/07 13:21:30 Key inclusion criteria
Key inclusion criteria
16 Update 2019/08/30 14:47:58 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address

Last name of contact person

Last name of contact person
Zip code
Address
Organization
Organization
Address
Address
Tel
Email
17 Update 2019/08/30 14:48:52 Number of participants that the trial has enrolled
18 Update 2019/08/30 14:54:05 Date of IRB
Anticipated trial start date
Date of closure to data entry
Date trial data considered complete
19 Update 2021/06/16 15:35:40
Last name of contact person

Last name of contact person
Name of person sending information
Name of person sending information
Organization
20 Update 2021/06/22 09:46:31 Homepage URL
21 Update 2022/07/14 16:01:28 Narrative objectives1
22 Update 2022/07/14 16:05:28 Interventions/Control_2
23 Update 2022/07/14 16:07:28 Division name
24 Update 2022/07/14 16:36:02 Recruitment status
25 Update 2022/07/14 16:48:14 URL releasing protocol
Publication of results
URL related to results and publications
Results
Results
Results date posted
Date of the first journal publication of results
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures
Plan to share IPD
Plan to share IPD
26 Update 2022/07/14 17:51:18 Institute
Institute
Co-sponsor
Co-sponsor
27 Update 2022/07/15 16:28:59 Institutions
28 Update 2022/07/16 20:17:56 Secondary IDs
Study ID_1
Org. issuing International ID_1
Org. issuing International ID_1